GlassScriptPhysician profile
Maryam Moinfar
NPI 1376515403
$6,726.54
in general payments reported to CMS, 2019-2025
32 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $437 · 2021: $1,053 · 2022: $1,070 · 2023: $1,458 · 2024: $1,087 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,596.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $692.30 | 2019-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $573.32 | 2019-2023 | |
| Merz North America, INC. | $543.08 | 2019-2025 | Xeomin |
| Abbvie INC. | $520.33 | 2019-2025 | |
| Surgenex LLC | $490.34 | 2025 | Ardeograft, Renograft, Surmatrix |
| Regeneron Healthcare Solutions, INC. | $466.32 | 2020-2025 | Libtayo, Dupixent |
| Incyte Corporation | $418.55 | 2022-2025 | Opzelura |
| Amgen INC. | $347.46 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $319.17 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $285.24 | 2019-2025 | Adbry |
| Janssen Biotech, INC. | $250.04 | 2019-2025 | Tremfya, Simponi, Stelara |
| Galderma Laboratories, L.P. | $237.41 | 2020-2024 | |
| Biofrontera INC. | $197.94 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Genzyme Corporation | $161.56 | 2019-2023 | |
| Dermavant Sciences, INC. | $158.02 | 2023-2024 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $138.18 | 2019-2021 | |
| Ucb, INC. | $134.86 | 2021-2025 | Bimzelx, Cimzia |
| Organogenesis INC. | $118.43 | 2023-2024 | Puraply |
| Mayne Pharma Commercial LLC | $98.79 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $98.48 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $86.30 | 2020 | |
| Almirall LLC | $56.80 | 2022 | |
| Allergan, INC. | $55.77 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.91 | 2019-2020 | |
| Lilly USA, LLC | $47.81 | 2024 | Taltz, Olumiant, Zepbound |
| Nabriva Therapeutics, Plc | $39.34 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $30.79 | 2021-2023 | |
| Vyne Pharmaceuticals INC. | $30.48 | 2021 | |
| Journey Medical Corporation | $21.57 | 2024 | |
| Verrica Pharmaceuticals INC. | $19.32 | 2024 | Ycanth |
| Misonix INC | $17.71 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $16.92 | 2025 | Genadur |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Moinfar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.